Lisata Therapeutics to Present at LD Micro Main Event XIX
Lisata Therapeutics (NASDAQ:LSTA) will present a corporate overview at LD Micro Main Event XIX in San Diego, California, taking place October 19–21, 2025. David J. Mazzo, Ph.D., President and CEO, is scheduled to present on Monday, October 20 at 10:30 a.m. PT. One-on-one investor meetings will be held throughout the conference. The presentation will be available for online viewing and interested parties can request meeting information or schedule a one-on-one by emailing jmenditto@lisata.com.
Lisata Therapeutics (NASDAQ:LSTA) terrà una panoramica aziendale a LD Micro Main Event XIX a San Diego, in California, che si svolgerà dal 19 al 21 ottobre 2025. David J. Mazzo, Ph.D., Presidente e CEO, è previsto presentare lunedì 20 ottobre alle ore 10:30 PT. Incontri one-to-one con investitori saranno organizzati durante l'intero evento. La presentazione sarà disponibile per la visione online e le parti interessate possono richiedere informazioni sull'incontro o prenotare un colloquio individuale inviando un'email a jmenditto@lisata.com.
Lisata Therapeutics (NASDAQ:LSTA) presentará una visión corporativa en LD Micro Main Event XIX en San Diego, California, que se celebrará del 19 al 21 de octubre de 2025. David J. Mazzo, Ph.D., Presidente y CEO, está programado para presentar el lunes 20 de octubre a las 10:30 a.m. PT. Se llevarán a cabo reuniones individuales con inversores durante toda la conferencia. La presentación estará disponible para su visualización en línea y las partes interesadas pueden solicitar información sobre reuniones o programar una reunión individual enviando un correo a jmenditto@lisata.com.
Lisata Therapeutics (NASDAQ:LSTA)는 LD Micro Main Event XIX에서 기업 개요를 발표할 예정이며, 이 행사는 미국 캘리포니아주 샌디에이고에서 2025년 10월 19–21일에 열립니다. David J. Mazzo, Ph.D., 사장 겸 최고경영자,는 2025년 10월 20일 월요일 오전 10:30(PT)에 발표할 예정입니다. 컨퍼런스 전 기간에 걸쳐 투자자와의 1:1 미팅이 진행됩니다. 발표는 온라인으로 시청 가능하며, 미팅 정보 요청이나 1:1 미팅 스케줄은 jmenditto@lisata.com으로 이메일로 문의하시면 됩니다.
Lisata Therapeutics (NASDQ:LSTA) présentera une vue d’ensemble de l’entreprise lors de LD Micro Main Event XIX à San Diego, Californie, qui se déroulera du 19 au 21 octobre 2025. David J. Mazzo, Ph.D., Président-directeur général, est prévu de présenter le lundi 20 octobre à 10h30 PT. Des réunions individuelles avec les investisseurs auront lieu pendant toute la conférence. La présentation sera disponible en ligne et les parties intéressées peuvent demander des informations sur les réunions ou programmer une rencontre individuelle en envoyant un courriel à jmenditto@lisata.com.
Lisata Therapeutics (NASDAQ:LSTA) wird bei LD Micro Main Event XIX in San Diego, Kalifornien, eine Unternehmensübersicht präsentieren, die vom 19. bis 21. Oktober 2025 stattfindet. David J. Mazzo, Ph.D., Präsident und CEO, wird voraussichtlich am Montag, dem 20. Oktober um 10:30 Uhr PT präsentieren. Einzelgespräche mit Investoren finden während der gesamten Konferenz statt. Die Präsentation wird online zur Ansicht verfügbar sein, und Interessierte können Informationen zu Meetings anfordern oder ein 1-zu-1-Gespräch vereinbaren, indem sie eine E-Mail an jmenditto@lisata.com senden.
Lisata Therapeutics (NASDAQ:LSTA) ستقدم لمحة عامة عن الشركة في LD Micro Main Event XIX في سان دييغو، كاليفورنيا، الذي سيعقد في 19–21 أكتوبر 2025. من المقرر أن يقدم ديفيد ج. مازو، دكتوراه، رئيس مجلس الإدارة والرئيس التنفيذي يوم الاثنين 20 أكتوبر في الساعة 10:30 صباحاً بتوقيت المحيط الهادئ. ستُعقد اجتماعات فردية مع المستثمرين طيلة المؤتمر. ستكون العرض متاحاً للمشاهدة عبر الإنترنت ويمكن للأطراف المهتمة طلب معلومات عن الاجتماعات أو جدولة اجتماع واحد-لواحد بإرسال بريد إلكتروني إلى jmenditto@lisata.com.
Lisata Therapeutics (NASDAQ:LSTA) 将在 LD Micro Main Event XIX 于加利福尼亚州圣地亚哥举行企业概览，时间为 2025年10月19–21日。David J. Mazzo, Ph.D., 总裁兼首席执行官，计划在2025年10月20日（星期一）太平洋夏令时 10:30进行演讲。整场会议将提供一对一的投资者会谈。该演示文稿将在线观看，感兴趣方可通过发送电子邮件至 jmenditto@lisata.com 索取会谈信息或安排一对一会谈。
- None.
- None.
Basking Ridge, New Jersey--(Newsfile Corp. - October 13, 2025) - Lisata Therapeutics, Inc. (NASDAQ: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata, will present a corporate overview at the LD Micro Main Event XIX Conference. The conference is being held in San Diego, California from October 19-21, 2025.
Lisata's presentation is scheduled for Monday, October 20th at 10:30 a.m. Pacific time, with one-on-one meetings to be held throughout the conference. The presentation will also be available for online viewing here. To receive additional information regarding Lisata's presentation or to schedule a one-on-one meeting, please email jmenditto@lisata.com.
About LD Micro Main Event XIX
The 2025 LD Micro Main Event XIX will run from October 19-21, 2025 at the Hotel del Coronado in San Diego, California. The first day will consist of registration, keynote speakers, and some gorgeous views of the Pacific. It will be followed by two full days of company presentations and one-on-one investor meetings concluded with a closing reception. This three-day event will feature around 120 companies, presenting in half-hour increments, and attending private meetings with investors. For registration information, please contact registration@ldmicro.com.
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata's cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform® technology. The Company expects to announce numerous milestones over the next 1.5 years and believes that its projected capital will fund operations through the fourth quarter of 2026, encompassing anticipated data milestones from its ongoing and planned clinical trials. For a comprehensive overview of certepetide's mechanism of action, please view our informative short film. For more information on the Company, please visit www.lisata.com.
Contact:
Investors:
Lisata Therapeutics
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@lisata.com
Media:
ICR Healthcare
Ally Stubin
Vice President
Phone: 646-667-1861
Email: ally.stubin@icrhealthcare.com
# # #
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/269816
FAQ
When will Lisata Therapeutics (LSTA) present at LD Micro Main Event XIX?
Who will present for Lisata Therapeutics (LSTA) at the October 2025 LD Micro conference?
How can investors watch Lisata Therapeutics (LSTA) presentation online on October 20, 2025?
How can I schedule a one-on-one meeting with Lisata Therapeutics (LSTA) at LD Micro Main Event XIX?
What are the dates and location for LD Micro Main Event XIX where LSTA will present?
Will Lisata Therapeutics (LSTA) hold investor meetings during the LD Micro conference?
